Diagnosis and classification of mast cell proliferative disorders: Delineation from immunologic diseases and non-mast cell hematopoietic neoplasms

Journal of Allergy and Clinical Immunology

Volumn 114, Issue 1, 2004, Pages 3-11

  Valent, Peter ^a   Sperr, Wolfgang R ^a   Schwartz, Lawrence B ^a   Horny, Hans Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aggressive systemic mastocytosis; AHNMD; ASM; Associated hematologic non MC lineage disease; c kit; classification; CM; criteria; Cutaneous mastocytosis; Mast cell; Mast cell leukemia; Mastocytosis; MC; MCL; SCF; SM; Stem cell factor; Systemic mastocytosis; tryptase

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CLADRIBINE; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; STEM CELL FACTOR; TRYPTASE;

BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CLINICAL FEATURE; CUTANEOUS MASTOCYTOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; ENDOCRINE DISEASE; ENZYME BLOOD LEVEL; GASTROINTESTINAL DISEASE; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOPATHOLOGY; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; URTICARIA PIGMENTOSA; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

EID: 3442901899     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.02.045     Document Type: Review

References (102)

1. Schwartz L.B. Mast cells and basophils. Schwartz L.B., Zweiman B. Inflammatory mechanisms of allergic diseases. 2002;3-42 Marcel Dekker, New York
2. Valent P., Sillaber C., Bettelheim P. The growth and differentiation of mast cells. Prog Growth Factor Res. 3:1991;27-41
3. Schwartz L.B., Sakai K., Bradford T.R., Ren S., Zweiman B., Worobec A.S., et al. the alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 96:1995;2702-2710
4. Sperr W.R., Jordan J.H., Fiegl M., Escribano L., Dirnhofer S., Semper H., et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 128:2002;136-141
5. Akin C., Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol. 127:2002;133-136
6. Kirshenbaum A.S., Goff J.P., Kessler S.W., Mican J.M., Zsebo K.M., Metcalfe D.D. Effects of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol. 148:1992;772-777
7. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood. 94:1999;2333-2342
8. Agis H., Willheim M., Sperr W.R., Wilfing A., Krömer E., Kabrna E., et al. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony forming cell. J Immunol. 151:1993;4221-4227
9. Rottem M., Okada T., Goff J.P., Metcalfe D.D. Mast cells cultured from peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/FcεRI- cell population. Blood. 84:1994;2489-2496
10. Valent P. The riddle of the mast cell: c-kit ligand as missing link? Immunol Today. 15:1994;111-114
11. Mitsui H., Furitsu T., Dvorak A.M., Irani A.M., Schwartz L.B., Inagaki N., et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A. 90:1990;735-739
12. Valent P., Spanblöchl E., Sperr W.R., Sillaber Ch., Agis H., Zsebo K., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture. Blood. 80:1992;2237-2245
13. Sillaber C., Strobl H., Bevec D., Ashman L.K., Butterfield J.H., Lechner K., et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol. 147:1991;4224-4228
14. Kitamura Y., Go S., Hatanaka S. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 52:1978;447-452
15. Kitamura Y., Go S. Decreased production of mast cells in Sl/Sld mice. Blood. 53:1979;492-497
16. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest. 92:1993;1736-1744
17. Feger F., Ribadeau Dumas A., Leriche L., Valent P., Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 127:2002;110-114
18. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 92:1995;10560-10564
19. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 12:1996;312-314
20. Longley B.J., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.-Z., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci U S A. 96:1999;1609-1614
21. Buttner C., Henz B.M., Welker P., Sepp N.T., Grabbe J. Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. J Invest Dermatol. 111:1998;1227-1231
22. Akin C., Kirschenbaum A.S., Semere T., Worobec A.S., Scott L.M., Metcalfe D.D. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 28:2000;140-147
23. Yavuz A.S., Lipsky P.E., Yavuz S., Metcalfe D.D., Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutations in the c-kit gene. Blood. 100:2002;661-665
24. Sperr W.R., Escribano L., Jordan J.H., Schernthaner G.H., Kundi M., Horny H.-P., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 25:2001;529-536
25. Valent P., Schernthaner G.H., Sperr W.R., Fritsch G., Agis H., Willheim M., et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev. 179:2001;74-81
26. Xia H.Z., Du Z., Craig S., Klisch G., Noben-Trauth N., Kochan J.P., et al. Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol. 159:1997;2911-2921
27. Shimizu Y., Sakai K., Miura T., Narita T., Tsukagoshi H., Satoh Y., et al. Characterization of adult-type mast cells derived from human bone marrow CD34+ cells cultured in the presence of stem cell factor and interleukin-6. Interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation. Clin Exp Allergy. 32:2002;872-880
28. Valent P., Ashman L.K., Hinterberger W., Eckersberger F., Majdic O., Lechner K., et al. Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood. 73:1989;1778-1785
29. Valent P., Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol. 52:1992;333-423
30. Dalton R., Chan L., Batten E., Eridani S. Mast cell leukemia: evidence for bone marrow origin of the pathological clone. Br J Haematol. 64:1986;397-406
31. Escribano L., Orfao A., Diaz-Agustin B., Villarrubia J., Cervero C., Lopez A., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implication. Blood. 91:1998;2731-2736
32. Schernthaner G.H., Jordan J.H., Ghannadan M., Agis H., Bevec D., Nuñez R., et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 98:2001;3784-3792
33. Escribano L., Díaz-Agustín B., Bellas C., Navalón R., Nuñez R., Sperr W.R., et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 25:2001;563-570
34. Ghannadan M., Hauswirth A., Schernthaner G.-H., Müller M.R., Klepetko W., Schatzl G., et al. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol. 127:2002;299-307
35. Jordan H., Walchshofer S., Jurecka W., Mosberger I., Sperr W.R., Wolff K., et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-xL. Hum Pathol. 32:2001;545-552
36. Horny H.P., Lange K., Sotlar K., Valent P. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immuno-histochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol. 56:2003;575-578
37. Parwaresch M.R., Horny H.-P., Lennert K. Tissue mast cells in health and disease. Path Res Pract. 179:1985;439-461
38. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 96:1991;2S-4S
39. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 108:1996;385-397
40. Valent P., Akin C., Sperr W.R., Horny H.P., Arock M., Lechner K., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 122:2003;1-23
41. Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 25:2001;519-528
42. Horny H.-P., Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 25:2001;543-551
43. Horny H.P., Valent P. Histopathological and immunophenotypical aspects of mastocytosis. Int Arch Allergy Immunol. 127:2002;115-117
44. Horny H.-P., Ruck M., Kaiserling E. Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer. 70:1992;459-468
45. Horny H.-P., Kaiserling E., Parwaresch M.R., Lennert K. Lymph node findings in generalized mastocytosis. Histopathology. 21:1992;439-446
46. Horny H.-P., Kaiserling E., Campbell M., Parwaresch M.R., Lennert K. Liver findings in generalized mastocytosis. A clinicopathologic study. Cancer. 63:1989;532-538
47. Metcalfe D.D. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol. 96:1991;45S-46S
48. Travis W.D., Li C.Y. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol. 1:1988;4-14
49. Caplan R.M. The natural course of urticaria pigmentosa. Arch Dermatol. 87:1963;146-157
50. Akin C., Scott L.M., Metcalfe D.D. Slowly progressing mastocytosis with high mast cell burden and no evidence of a non-mast cell hematologic disorder: an example of a smoldering case? Leuk Res. 25:2001;635-638
51. Jordan J.H., Fritsche-Polanz R., Sperr W.R., Mitterbauer G., Födinger M., Schernthaner G.H., et al. A case of smouldering mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res. 25:2001;627-634
52. Hauswirth A., Sperr W.R., Ghannadan M., Schernthaner G.-H., Jordan J.H., Fritsche-Planz R., et al. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res. 26:2002;601-606
53. Sotlar K., Marafioti T., Griesser H., Theil J., Aepinus C., Jaussi R., et al. Detection of c-kit mutation Asp-816-Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukemia. Mol Pathol. 53:2000;188-193
54. Valent P., Akin C., Sperr W.R., Horny H.-P., Metcalfe D.D. Smouldering mastocytosis: a new type of systemic mastocytosis with slow progression. Int Arch Allergy Immunol. 127:2002;137-139
55. Valent P., Horny H.-P., Li C.Y., Longley J.B., Metcalfe D.D., Parwaresch R.M., et al. Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology and genetics. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Tumours of haematopoietic and lymphoid tissues. Vol 1. World Health Organization. 2001;291-302 IARC Press, Lyon, France
56. Valent P., Akin C., Sperr W.R., Horny H.-P., Metcalfe D.D. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 17:2003;1227-1241
57. Horny H.-P., Ruck M., Wehrmann M., Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol. 76:1990;186-193
58. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., Gralnick H.R. Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 91:1991;612-624
59. Sperr W.R., Horny H.-P., Lechner K., Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma. 37:2000;473-486
60. Travis W.D., Li C.Y., Yam L.T., Bergstralh E.J., Swee R.G. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 62:1988;965-972
61. Valent P., Horny H.-P., Escribano L., Longley J.B., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of Year 2000 Working Conference on Mastocytosis. Leuk Res. 25:2001;603-625
62. Valent P., Escribano L., Parwaresch M.R., Schemmel V., Schwartz L.B., Sotlar K., et al. Recent advances in mastocytosis research. Int Arch Allergy Immunol. 120:1999;1-7
63. Horny H.-P., Sillaber C., Menke D., Kaiserling E., Wehrmann M., Stehberger B., et al. Diagnostic utility of staining for tryptase in patients with mastocytosis. Am J Surg Pathol. 22:1998;1132-1140
64. Li W.V., Kapadia S.B., Sonmez-Alpan E., Swerdlow S.H. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozym, and CD20 antibodies. Mod Pathol. 9:1996;982-988
65. Li C.-Y. Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry. Leuk Res. 25:2001;537-541
66. Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res. 25:2001;553-562
67. Longley B.J., Reguera M.J., Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 25:2001;571-576
68. Prokocimer M., Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. Am J Clin Pathol. 75:1981;34-38
69. Valent P., Sperr W.R., Samorapoompichit P., Geissler K., Lechner K., Horny H.P., et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res. 25:2001;595-602
70. Jordan J.H., Sperr W.R., Lechner K., Geissler K., Schernthaner G.-H., Fritsche-Polanz R., et al. Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to novel SM-criteria. Leuk Lymphoma. 43:2002;575-582
71. Valent P., Samorapoompichit P., Sperr W.R., Horny H.-P., Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J. 3:2002;90-94
72. Austen K.F. Systemic mastocytosis. N Engl J Med. 326:1992;639-640
73. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 27:2003;635-641
74. Travis W.D., Li C.Y., Hogaland H.C., Travis L.B., Banks P.M. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc. 61:1986;957-966
75. Hartmann K., Henz B.M. Cutaneous mastocytosis - clinical heterogeneity. Int Arch Allergy Immunol. 127:2002;143-146
76. Escribano L., Akin C., Castells M., Orfao A., Metcalfe D.D. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 81:2002;677-690
77. Castells M., Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 127:2002;147-152
78. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol North Am. 14:2000;659-687
79. Sperr W.R., Jordan J.H., Baghestanian M., Kiener H., Samorapoompichit P., Semper H., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 98:2001;2200-2209
80. Schwartz L.B., Metcalfe D.D., Miller J.S., Earl H., Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 316:1987;1622-1626
81. Tefferi A., Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 11:2004;58-64
82. Wimazal F, Schwarzmeier J, Sotlar K, Simonitsch I, Sperr WR, Fritsche-Polanz R, et al. Splenic mastocytosis: report of two cases and detection of the transforming c-kit mutation D816V. Leuk Lymphoma. In press.
83. Horny H.-P., Parwaresch M.R., Kaiserling E., Muller K., Olbermann M., Mainzer K., et al. Mast cell sarcoma of the larynx. J Clin Pathol. 39:1986;596-602
84. Kojima M., Nakamura S., Itoh H., Ohno Y., Masawa N., Joshita T., et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol. 12:1999;739-743
85. Guenther P.P., Huebner A., Sobottka S.B., Neumeister V., Weissbach G., Todt H., et al. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol. 23:2001;134-138
86. Sperr W.R., Stehberger B., Wimazal F., Baghestanian M., Schwartz L.B., Kundi M., et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma. 43:2002;1097-1105
87. Casassus P., Caillat-Vigneron N., Martin A., Simon J., Gallais V., Beaudry P., et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 119:2002;1090-1097
88. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., Wolthers B.G., Kluin P.M., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 326:1992;619-623
89. Delaporte E., Pierard E., Wolters B.G., Desreumaux P., Janin A., Cortot A., et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol. 132:1995;479-482
90. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., Metcalfe D.D. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma. 22:1996;501-508
91. Weide R., Ehlenz K., Lorenz W., Walthers E., Klausmann M., Pfluger K.H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol. 72:1996;41-43
92. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 138:1998;489-495
93. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., Koller E., Sperr W.R., Lechner K., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 28:2004;249-257
94. Tefferi A., Li C.Y., Butterfield J.H., Hoagland H.C. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 344:2001;307-309
95. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., Van't Wout J.W., Verhoef G., Gerrits W.B., et al. Cladribine therapy for systemic mastocytosis. Blood. 102:2003;4270-4276
96. Escribano L., Perez de Oteyza J., Nunez R., Orfao A. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res. 26:2002;1043-1046
97. Tefferi A. Treatment of systemic mast cell disease: beyond interferon. Leuk Res. 28:2004;223-224
98. Akin C., Brockow K., D'Ambrosio C., Kirshenbaum A.S., Ma Y., Longley B.J., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 31:2003;686-692
99. Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., Metcalfe D.D. A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood. 2003;. In press
100. Zermati Y., De Sepulveda P., Feger F., Letard S., Kersual J., Casteran N., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 22:2003;660-664
101. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 102:2003;3093-3096
102. Fritsche-Polanz R., Jordan J.H., Feix A., Sperr W.R., Sunder-Plassmann G., Valent P., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 113:2001;357-364